• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Beigene Ltd ADR (NQ: BGNE )

    201.99 +3.40 (+1.71%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 20, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 411,783
    Open 205.67
    Bid (Size) 201.00 (1)
    Ask (Size) 215.22 (1)
    Prev. Close 198.59
    Today's Range 200.98 - 208.28
    52wk Range 126.97 - 215.00
    Shares Outstanding 1,211,067,023
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Chinese Biotech BeiGene Labeled 'Unique Investment' As Analyst Confident In Lead Cancer Drug
    JMP Securities has initiated coverage on BeiGene highlighting the Chinese biotech company as a 'unique investment opportunity.' The firm's leading drug, Brukinsa (zanubrutinib), is emerging in the... 
    Via Benzinga
    What Analysts Are Saying About BeiGene Stock
    Via Benzinga

    Performance

    YTD
    +14.12%
    +14.12%
    1 Month
    +4.01%
    +4.01%
    3 Month
    +29.86%
    +29.86%
    6 Month
    +23.39%
    +23.39%
    1 Year
    +4.74%
    +4.74%

    More News

    Read More
    Oxford Industries Reports Weak Results, Joins Viper Energy And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
    Via Benzinga
    Why Champions Oncology Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Top 2 Health Care Stocks That May Plunge In August
    Via Benzinga
    BeiGene Announces Updates to Commercial Leadership Team
    From BeiGene, Ltd.
    Via Business Wire
    Innovent Bio hopes for plus-sized profits from obesity drug
    Via Benzinga
    Topics Retirement
    Exposures Pension
    Week In Review: UCB Sells China Drug Portfolio To CBC For $680 Million
    Via Talk Markets
    BeiGene to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
    From BeiGene, Ltd.
    Via Business Wire
    BeiGene’s BGB-16673 Receives U.S. FDA Fast Track Designation for CLL/SLL
    From BeiGene, Ltd.
    Via Business Wire
    Cancer Medicines From Merck, Bristol Myers And BeiGene In Question, As FDA Committee To Discuss Limiting PD-1 Drugs For Stomach Cancer
    Via Benzinga
    Exposures Product Safety
    BeiGene Enters Next Phase of Global Growth with Announcement of Second Quarter 2024 Financial Results and Corporate Updates
    From BeiGene
    Via Business Wire
    Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal
    Via Talk Markets
    BeiGene Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility, Continues Global Expansion to Deliver Medicines to More Patients Around the World
    From BeiGene, Ltd.
    Via Business Wire
    AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now?
    Via The Motley Fool
    BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer
    From BeiGene, Ltd.
    Via Business Wire
    Moderna And Walgreens Boots Alliance Were Among The 10 Biggest Large Cap Losers Last Week (June 23 - June 29): Are These In Your Portfolio?
    Via Benzinga
    What's Going On With Small-Cap Cancer Focused Nurix Therapeutics On Monday?
    Via Benzinga
    Week In Review: Osaka Enters $445 Million Deal For Two Hearing Loss Candidates From France's Cilcare
    Via Talk Markets
    BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024
    From BeiGene, Ltd.
    Via Business Wire
    BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
    From BeiGene, Ltd.
    Via Business Wire
    7 Large-Cap Stocks That Can Jump 50% By 2025
    Via InvestorPlace
    Lululemon Athletica Was Among The Worst-Performing Stocks Last Week (May 19-May 26, 2024): Are These 10 Large-Cap Stock Losers In Your Portfolio?
    Via Benzinga
    Week In Review: Hengrui And Degron Announce $7.2 Billion In Drug Licensings
    Via Talk Markets
    BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL
    From BeiGene, Ltd.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.